Articles tagged with Ovarian Cancer
A new study aims to discover the genetic and molecular underpinnings of small cell carcinoma of the ovary (SCCO), a rare and aggressive cancer affecting young women. Researchers will collect tumor and blood samples using advanced genomic approaches to understand the disease's origins and develop effective treatments.
In a Phase I trial, MK-4827 demonstrated anti-tumour responses in both sporadic and BRCA1/2 mutation-associated cancers. Patients with exhausted standard therapies showed significant shrinkage or stabilization of tumours for extended periods.
Using OncoMap, researchers can identify specific mutations in oncogenes that drive ovarian cancer growth and choose targeted drugs to halt tumor progression. The technique holds promise for personalized medicine in treating advanced ovarian cancer.
Researchers at the Centenary Institute discovered a new death pathway that can break drug resistance in ovarian cancer. The treatment, FTY720, kills ovarian cancer cells through necrosis, making it resistant to relapse. Further clinical trials are needed to confirm its effectiveness.
A study analyzing European Prospective Investigation into Cancer and Nutrition data found that current hormone therapy use increases the risk of ovarian cancer by 29%. The risk did not differ by type or duration of hormone therapy, suggesting a potential long-term hazard.
A study found that a peptide being tested to treat atherosclerosis significantly inhibited the growth of ovarian cancer in human cell lines and mouse models. The peptide, an apoA-I mimetic, was shown to be effective when administered via injection or ingestion, with minimal side effects.
Dr Clare Scott's VCA fellowship aims to uncover the origins of ovarian cancer and develop new laboratory models for studying human cancers. The funding will also support the use of a web portal, CART-WHEEL.org, to coordinate patient information and research studies.
The Program in Women's Oncology at Women & Infants Hospital will receive a $5,000 donation from Pink Heals Rhode Island to support the Patient Advocate Program. The program helps eliminate obstacles and stresses for women battling breast cancer by arranging transportation, financial assistance, and other services.
Women who inherit BRCA1 or BRCA2 gene mutations from their father are at increased risk of breast and ovarian cancer, yet this risk is often overlooked. A study found that patients with a paternal family history of cancer were 5 times more likely to be referred for genetic testing than those with a maternal family history.
A new study found that estrogen replacement therapy significantly speeds up ovarian cancer growth and increases the likelihood of cancer metastasizing to the lymph nodes. Researchers discovered estrogen-regulated genes specific to ER+ ovarian cancer that can be targeted with new anti-estrogen therapies.
A renowned gynecologic oncologist expresses concerns about a major ovarian cancer study, highlighting the need for targeted genetics-based treatments over delayed treatment timing. The study found no significant difference in survival rates between early and delayed chemotherapy groups.
A randomized study found that adding topotecan to carboplatin and paclitaxel did not improve progression-free survival in patients with ovarian cancer, but increased toxicity. The standard regimen of carboplatin and paclitaxel remains the best care for epithelial ovarian cancer.
A Phase II clinical trial of MLN8237, a selective Aurora A kinase inhibitor, demonstrates single-agent activity with durable disease control in some patients with ovarian cancer resistant to platinum-based chemotherapy. The study found encouraging responses in several patients, suggesting potential for future combination therapies.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
A new randomised trial shows that starting chemotherapy earlier does not improve survival or quality of life for women with relapsed ovarian cancer. The study found that patients who received early treatment experienced a faster deterioration in quality of life, including role, emotional, social, and fatigue symptoms.
Research published in Annals of Oncology suggests that intrauterine devices releasing progestin hormone levonorgestrel combined with GnRH injections can halt and reverse cancer growth in women aged 40 or younger. The treatment has shown promise in treating specific types of endometrial cancer, preserving fertility for young women.
A consortium of cancer researchers has identified four chromosome locations with genetic changes that may alter a woman's risk of developing ovarian cancer. These findings are based on a large genome-wide association study and could lead to individualized risk assessments for ovarian cancer.
Two studies found new genetic variants linked to ovarian cancer risk in the general population, particularly in women with serous ovarian cancer. The variants were more common in women with aggressive disease and may be used for closer surveillance and preventive approaches.
Researchers have identified two genes, ARID1A and PPP2R1A, whose mutations are linked to ovarian clear cell carcinoma, a highly aggressive form of ovarian cancer. The study found that ARID1A mutations were present in over half of the tumors studied, suggesting a significant role in this type of cancer.
A long-term study found that women with BRCA1 and BRCA2 genetic mutations significantly reduced their risk of breast and ovarian cancer with preventive surgeries. Risk-reducing mastectomies and removal of the fallopian tubes and ovaries lowered cancer risks, including those with prior breast cancer.
Prophylactic mastectomy and salpingo-oophorectomy significantly reduce breast and ovarian cancer risks in women with BRCA1/2 mutations. The study found that risk-reducing mastectomy decreased breast cancer risk, while salpingo-oophorectomy lowered ovarian cancer risk.
Women with a family history of breast or ovarian cancer can benefit from prophylactic surgeries to remove ovaries, fallopian tubes, or breasts, increasing survival rates and eliminating risk. Genetic testing is crucial for identifying the BRCA1 and BRCA2 genes, which significantly increase cancer risk.
Researchers found that EZH2 promotes tumor growth by shutting down genes that block formation of new blood vessels. Silencing EZH2 in ovarian cancer tumors reduced average tumor weight by 62% and increased programmed death of tumor cells.
The study found that depleting SIK2 from ovarian cancers sensitized the cells to paclitaxel, making it more effective in stopping cancer growth. Levels of SIK2 protein are increased in approximately 30 percent of ovarian cancers and associated with poorer survival rates.
Researchers have discovered a protein called Salt Inducible Kinase 2 (SIK2) that plays a key role in regulating cell division and may be an attractive target for treating ovarian cancer. Combination therapies targeting different phases of the cell cycle are highly desirable for optimal cancer treatment.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
The new test uses mass spectrometry to analyze metabolites in a single drop of blood serum, accurately identifying women with ovarian cancer in all tested patients. Further testing will be conducted on 500 patients to confirm the results and explore its potential for detecting other types of cancers.
A recent study suggests that a new drug, Olaparib, can reduce tumor size in women with advanced hereditary ovarian and breast cancers, offering a promising targeted therapy approach. The Phase II trials showed significant shrinkage in tumor size and relatively mild toxicities.
Researchers at Yale University have discovered a genetic marker that can help predict ovarian cancer risk. The KRAS-variant was found in 25% of all ovarian cancer patients and 61% of those with a family history of breast and ovarian cancer, suggesting it may be a new marker for high-risk families.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
A new study reveals that shorter leukocyte telomere length is associated with a significantly increased risk of developing cancer and dying from cancer. Participants with the shortest telomere lengths had approximately three times the risk of cancer compared to those in the longest group.
Two phase-2 trials demonstrate the efficacy of olaparib in treating advanced ovarian and breast cancer in patients with BRCA1 or BRCA2 mutations. The higher dose of olaparib showed better treatment response rates compared to the lower dose, with ORR of 33% and 41% respectively.
Researchers at Arizona State University and Fred Hutchinson Cancer Research Center develop a new method to identify biomarkers for ovarian cancer using antibodies. They found 19 distinct scFvs that selectively bound to proteins exclusively found in ovarian cancerous blood serum, providing potential for significant improvements in patie...
A phase I clinical trial of the combination of decitabine and carboplatin has shown promising results in treating late-stage ovarian cancer, with four patients experiencing no disease progression after six months. The treatment regimen has been found to be well-tolerated, with mild adverse reactions.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
Researchers found that CA-125 change over time can detect invasive, high-grade ovarian cancers at curable stages in post-menopausal women. The study identified a promising first step towards screening, but acknowledges the need for further research and a large-scale randomized trial to confirm the findings.
Researchers found that flaxseed-enriched diets decreased late-stage ovarian tumor severity and increased survival rates in hens. The study also showed improved weight control and reduced metastatic spread in hens fed the flaxseed diet, suggesting potential benefits for human ovarian cancer treatment.
Researchers found that curcumin nanoparticles, delivered via nanoparticles, increased the sensitivity of resistant ovarian cancer cells to chemotherapy and radiation. The treatment enables lower doses of cisplatin and radiation, improving therapeutic outcomes without increasing toxicity.
Fox Chase researchers have discovered that early ovarian cancers arise in inclusion cysts of the ovary. The team found gene expression patterns and extra chromosomes in cells from these cysts compared to normal surface epithelium cells.
Researchers have found that patients with hereditary ovarian cancer are more likely to experience secondary tumours in their liver and spleen, despite better overall prognosis. A new approach suggests testing these patients for BRCA1 and BRCA2 genes to ensure tailored treatment.
Researchers have identified a new breast and ovarian cancer susceptibility gene, RAD51C, in a German study. The gene is associated with a high risk of breast and ovarian cancer, particularly in familial cases.
The Anne Rita Monahan Foundation has raised $50,000 for ovarian cancer research at the Translational Genomics Research Institute (TGen). Funds from the 2nd annual Tea for TEAL event will support the development of a reliable screening test and precision therapy for ovarian cancer.
Researchers at Fox Chase Cancer Center have isolated an engineered antibody, GS45, that targets the Müllerian Inhibiting Substance Type II Receptor on ovarian cancer cells. This unique target is scarce in normal tissue, reducing the risk of side effects associated with traditional targeted therapies.
Chronic stress accelerates tumor growth in ovarian cancer patients by protecting cells from anoikis, a process that allows tumor cells to survive and grow. Stress hormones norepinephrine and epinephrine activate the protein FAK, leading to accelerated mortality.
Researchers found that stress-activated protein protects fugitive ovarian cancer cells from programmed death, allowing them to escape the primary tumor and metastasize. The study suggests that restoring cancer cells' vulnerability to anoikis could suppress tumor growth and metastasis.
Researchers find that stress hormones can protect ovarian cancer cells from anoikis, promoting tumor growth. Higher levels of activated FAK are linked to accelerated mortality in ovarian cancer patients.
A recent study published in the Journal of Clinical Oncology found that women with breast cancer before age 55 who carry an inherited mutation in BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite their initial tumor. The study revealed a higher risk of contralateral breast cancer among younger women wit...
Researchers from the University of Gothenburg found that women with a known Western Swedish mutation in the BRCA1 gene have an increased risk of developing ovarian cancer. The study suggests that women without this mutation do not face an elevated risk, and provides clarity for targeted screenings.
Despite progress in cancer research, the disease remains a leading cause of death in the US. Advances in primary prevention, early detection, and treatment have improved outcomes for many cancers, but significant challenges remain, including the need for improved therapies.
Researchers found that microRNA-31 regulates the protein IFITM-1, which contributes to chemoresistance in ovarian cancer. Identifying this microRNA could lead to a therapeutic target for overcoming chemotherapy resistance.
A new study suggests that elective removal of ovaries during hysterectomy may not be beneficial and could even increase the risk of other health problems. The study analyzed data from over 300,000 women who underwent the procedure, finding a link between oophorectomy and increased risks of coronary artery disease and hip fractures.
Researchers found that GP referrals for gynaecological investigation were delayed for older women with suspected ovarian cancer. Women over 70 years old had a 20-week wait for referral, while those aged 75-79 years had a peak wait of 24 weeks. The discrepancy may be due to differences in data recording and GPs' motivation.
Businessman-philanthropist Foster Friess will match donations up to $50,000 to support TGen's ovarian cancer research. The event has already raised nearly $38,000, with over 500 participants expected.
A new study published in the Journal of the American Dietetic Association found a strong relationship between healthy eating and prolonged ovarian cancer survival. Higher consumption of fruits, vegetables, and healthier grains was associated with improved survival rates.
Dr Clare Scott and Dr Marnie Blewitt have been awarded fellowships worth AU$1.75 million to focus on lymphoma and breast cancer, respectively. Their research aims to improve outcomes for cancer patients by harnessing the body's natural killing machinery.
POSITIVE RESULTS is a comprehensive guidebook for those at high risk of breast and ovarian cancer, providing insights into genetics, diagnosis, and treatment options. The book offers a supportive approach to navigating complex decisions, covering genetic testing, screening, mastectomy, and more.
Researchers at Georgia Tech have developed a potential new treatment against ovarian cancer using magnetic nanoparticles to attach to and remove cancer cells from the body. The technique has shown promising results in both mouse and human cancer samples.
Researchers found that ovarian cancer symptoms are not reliable for detecting the disease at an early stage. In fact, only 1 out of 100 women with symptoms will be diagnosed with ovarian cancer. This study highlights the need for better molecular markers and imaging modalities to improve screening for ovarian cancer.
Researchers at Yale University have discovered that stopping the expression of two genes Lin28 and Oct4 can reduce ovarian cancer cell growth and survival. This could lead to more effective treatments for this deadly form of cancer, which has a high recurrence rate and resistance to treatment.
Researchers discovered a noninvasive contrast-enhanced ultrasound imaging technique that can aid in the detection of early-stage ovarian cancer when combined with proteomic blood analyses. This method has shown high accuracy and the potential to save lives by detecting disease at an early stage.